Lifesaving shortcuts in gene testing.
The genomic sequencing giant has managed to spur personalized drug development, help foster a revolution in at-home DNA testing, and even save critically ill newborns. The company has been at the forefront of making whole genomic sequencing not just cheaper (it now costs less than $1,000 to conduct such sequencing, as opposed to the $3 billion it cost to sequence the first full human genome—largely thanks to Illumina’s work over the past 20 years)—but also considerably faster.
That’s absolutely critical when it comes to saving newborns in the ICU suffering from rare genetic disorders, according to Dr. Stephen Kingsmore, the CEO of Rady Children’s Institute for Genomic Medicine in San Diego. “Illumina is involved in every step of delivering care for these sick babies,” he says. Kingsmore says that, thanks to Illumina’s technology and dedication to making whole genomic sequencing accessible, affordable, and fast, a critically ill baby can have his or her genome sequenced in as little as 20 hours—which means that child can have personalized treatment delivered within a matter of days rather than weeks, likely spelling the difference between life and death. The Rady Institute has already tested about 1,000 sick newborns with Illumina’s tech in the past three years (about half of them in the past 12 months).
|Impact Segment||Public Health/Nutrition|
|Industry||Scientific, Photographic and Control Equipment|
|Prior Year Rank||-|
|Revenues ($M) (Last Fiscal Year)||$3,333|
|Profits ($M) (Last Fiscal Year)||$826|
|Market Value ($M) as of 8/12/19||$42,680|